RecruitingNCT05283993

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH

Sponsor

Peking University First Hospital

Enrollment

2,000 participants

Start Date

Jul 1, 2021

Study Type

OBSERVATIONAL

Conditions

Multiple Myeloma Amyloidosis Smoldering Multiple Myeloma Plasma Cell Leukemia Cryoglobulinemia Castleman's Disease Light Chain Deposition Disease Heavy Chain Deposition Disease Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Renal Significance (MGRS)Monoclonal Gammopathy of Neurological Significance (MGNS)

Summary

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.

Eligibility

Plain Language Summary

Simplified for easier understanding

This is an observational cohort study that collects medical data over time from patients with plasma cell disorders (PCDs) — a group of conditions involving abnormal antibody-producing cells — at Peking University First Hospital. PCDs include multiple myeloma, amyloidosis, and related conditions. The goal is to better understand how these diseases progress and respond to treatment in real-world practice. **You may be eligible if...** - You have a confirmed diagnosis of a plasma cell disorder (including multiple myeloma, smoldering myeloma, amyloidosis, and related conditions) - You are admitted to or treated at Peking University First Hospital - You have signed an informed consent form to share your data **You may NOT be eligible if...** - You have a serious other illness that could be life-threatening and would confound the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.